SEER-2 (Neurotrophic Keratopathy) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an investigational drug called RGN-259 Thymosin Beta 4 eye drops solution (the study drug) is a safe and effective option for the treatment of neurotrophic keratopathy.
Neurotrophic Keratopathy
Who Can Participate in the Study?
Adults ages 18+ who:
- Have persistent epithelial defect in one or both eyes
- Are diagnosed with neurotrophic keratopathy
- Have not had any eye surgery for the last 3 months
For more information about who can be in this study, please contact the study team at DEC-RA@duke.edu.
What is Involved?
If you choose to join the study, you will
- Get a random assignment (like a coin flip) to receive either the study drug or a placebo (sterile saline solution)
- Visit our clinic at the Duke Eye Center up to 7 times
- Keep in touch with the study team for up to 6 weeks
During the study visits, you will have eye exams and vision tests, and you will answer some questionnaires.
Study Details
